Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.46 EUR
Change Today +0.012 / 0.22%
Volume 0.0
TG4 On Other Exchanges
Symbol
Exchange
EN Brussels
OTC US
Berlin
As of 9:32 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

thrombogenics nv (TG4) Snapshot

Open
€5.29
Previous Close
€5.44
Day High
€5.46
Day Low
€5.26
52 Week High
05/7/14 - €23.60
52 Week Low
04/2/15 - €4.69
Market Cap
196.9M
Average Volume 10 Days
190.0
EPS TTM
--
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THROMBOGENICS NV (TG4)

Related News

No related news articles were found.

thrombogenics nv (TG4) Related Businessweek News

No Related Businessweek News Found

thrombogenics nv (TG4) Details

ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes ophthalmic and oncology medicines in Belgium and internationally. The company’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat various disorders, such as cancer, age-related macular degeneration, retinopathy, and inflammation; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc. to provide clinical research services for the development of JETREA. The company was founded in 1991 and is headquartered in Leuven, Belgium.

120 Employees
Last Reported Date: 04/4/15
Founded in 1991

thrombogenics nv (TG4) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €690.0K
Executive Director
Total Annual Compensation: --
Executive Director and Member of Audit Commit...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

thrombogenics nv (TG4) Key Developments

ThromboGenics NV Presents at CF&B European Small Cap Event, Apr-27-2015

ThromboGenics NV Presents at CF&B European Small Cap Event, Apr-27-2015 . Venue: Paris, France.

ThromboGenics NV Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion

ThromboGenics NV announced that it is evaluating JETREA as a potential treatment for Retinal Vein Occlusion. RVO is the third indication ThromboGenics has underway for JETREA. The new research will build on earlier ThromboGenics Phase IIa data pointing out the potential of ocriplasmin for the treatment of peripheral arterial occlusions. With this new vitreo-retinal project, ThromboGenics will demonstrate the potential of using locally delivered ocriplasmin for lysing the blood clots that are responsible for this sight threatening condition. In support of this research, ThromboGenics has secured a €0.6 million grant from the Flemish Agency for Innovation by Science and Technology. The company will use this grant to evaluate ocriplasmin's ability to lyse the clots that cause RVO by local intravenous administration of this thrombolytic agent in pre-clinical models of the disease. For that, the company will collaborate with the Ophthalmology Department of the University Hospital UZLeuven in Belgium. The grant will also support a partnership of ThromboGenics with the Mechanical Engineering Department of the KU Leuven. The Department is developing a robotic-assisted system which has the capacity to deliver local administration of ocriplasmin in the retinal veins. At present, there is no treatment option for clearing retinal veins of RVO-patients. The current standard of care for RVO primarily focuses on the treatment of visual impairment due to macular edema resulting from an existing retinal vein occlusion. Although the current treatment paradigm improves the vision of the patient, it comes with a relatively high cost associated with continued drug administrations and follow up by the physician.

ThromboGenics and VIB Launch New Oncology Company, Oncurious NV

ThromboGenics NV announced the foundation of Oncurious NV, a new oncology company that will develop TB-403 for the treatment of pediatric brain tumors. VIB will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. VIB will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. TB-403 is a humanized monoclonal antibody against placental growth factor. PlGF is expressed in several types of cancer, including medulloblastoma. High expression of the PlGF receptor neuropilin 1 has been shown to correlate with poor overall survival. Medulloblastoma is a rare, life-threatening brain tumor that mainly affects children. Treatment with TB-403 in relevant animal models for medulloblastoma has demonstrated beneficial effects on tumor growth and survival. The antibody can potentially be used in other pediatric cancer indications, including neuroblastoma. Oncurious now plans to start a Phase I/IIa program with TB-403 in medulloblastoma patients. Enrollment of the first patient is expected for the end of 2015. The favorable safety profile of TB-403 has already been demonstrated in clinical trials in patients with other diseases. BioInvent International AB will act as a co-development partner for this oncology project. ThromboGenics has retained the exclusive license for use of TB-403 in ophthalmic indications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TG4:GR €5.46 EUR +0.012

TG4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TG4.
View Industry Companies
 

Industry Analysis

TG4

Industry Average

Valuation TG4 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.9x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit www.thrombogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.